Guided Capital Wealth Management LLC purchased a new position in shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 43,953 shares of the company's stock, valued at approximately $1,794,000. Establishment Labs makes up approximately 1.5% of Guided Capital Wealth Management LLC's investment portfolio, making the stock its 22nd largest position. Guided Capital Wealth Management LLC owned approximately 0.15% of Establishment Labs as of its most recent SEC filing.
A number of other hedge funds have also modified their holdings of ESTA. Quarry LP acquired a new stake in Establishment Labs during the fourth quarter worth approximately $27,000. KLP Kapitalforvaltning AS acquired a new stake in shares of Establishment Labs in the 4th quarter worth approximately $161,000. Elevation Point Wealth Partners LLC acquired a new stake in shares of Establishment Labs in the 1st quarter worth approximately $207,000. Patriot Financial Group Insurance Agency LLC acquired a new stake in Establishment Labs during the first quarter valued at approximately $234,000. Finally, Hood River Capital Management LLC lifted its stake in Establishment Labs by 236.4% during the fourth quarter. Hood River Capital Management LLC now owns 5,920 shares of the company's stock valued at $273,000 after purchasing an additional 4,160 shares during the last quarter. 72.91% of the stock is owned by hedge funds and other institutional investors.
Establishment Labs Stock Performance
Shares of NASDAQ:ESTA traded down $0.22 on Friday, hitting $37.81. The company had a trading volume of 197,533 shares, compared to its average volume of 473,481. The company has a current ratio of 3.36, a quick ratio of 2.05 and a debt-to-equity ratio of 5.72. The stock has a 50 day moving average price of $34.66 and a 200 day moving average price of $37.01. Establishment Labs Holdings Inc. has a 1-year low of $26.56 and a 1-year high of $52.41. The stock has a market cap of $1.09 billion, a price-to-earnings ratio of -12.20 and a beta of 0.74.
Establishment Labs (NASDAQ:ESTA - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported ($0.70) EPS for the quarter, beating the consensus estimate of ($0.83) by $0.13. Establishment Labs had a negative net margin of 52.34% and a negative return on equity of 196.25%. The business had revenue of $41.38 million for the quarter, compared to the consensus estimate of $41.15 million. During the same period in the prior year, the company posted ($0.58) earnings per share. Establishment Labs's revenue was up 11.3% compared to the same quarter last year. Analysts expect that Establishment Labs Holdings Inc. will post -2.41 EPS for the current year.
Analyst Ratings Changes
Several research firms have weighed in on ESTA. Wall Street Zen upgraded shares of Establishment Labs from a "sell" rating to a "hold" rating in a research note on Saturday, June 14th. BTIG Research initiated coverage on shares of Establishment Labs in a research note on Friday, May 16th. They issued a "buy" rating and a $62.00 target price for the company. Stephens restated an "overweight" rating and set a $52.00 target price on shares of Establishment Labs in a research report on Thursday, March 6th. Finally, Needham & Company LLC restated a "buy" rating and issued a $48.00 price target on shares of Establishment Labs in a report on Friday, June 13th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $52.40.
Check Out Our Latest Report on ESTA
Establishment Labs Company Profile
(
Free Report)
Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.
See Also
Before you consider Establishment Labs, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Establishment Labs wasn't on the list.
While Establishment Labs currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
